Testing Whether Gene Testing of Tumor Tissue or Blood Helps Guide Treatment Choices
Original title: The Added Value of Tissue or Liquid Biopsy NGS Profiling in Advanced Solid Tumor Treatment Decisions.
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
The trial does not list a phase, so we treat it as an early study in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial looks at whether detailed gene testing of a tumor sample or a blood sample helps doctors pick the next treatment.
Who this trial is for. This trial is for people with a solid tumor that has spread, or a primary tumor of the brain or spinal cord. It plans to include 550 patients at 14 centers. Patients with a tissue sample get gene testing on that tissue. Patients without a tissue sample get testing on a blood sample instead.
Where it stands. This trial has not reported results. It is looking at what these gene tests add to treatment decisions. The answer is not in yet.
What this means, and what it doesn't
What it could mean: Gene testing like this is still being studied, so it is not settled care. If this sounds like your situation, you can ask your care team about it. They can tell you if testing like this makes sense for you.
What it doesn't mean: This does not mean the testing works. A trial is a test, not a proven treatment. Joining a trial is not a guarantee that it will help you. It is not a promise of a cure. And no one can promise you a spot. The trial team decides who can take part.
Source: ClinicalTrials.gov, July 20, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.